Q1 2026 Glaukos Corp Earnings Call Transcript
Key Points
- Glaukos Corp (GKOS) reported record first-quarter consolidated net sales of $150.6 million, marking a 41% increase on a reported basis and 39% on a constant currency basis compared to the previous year.
- The company raised its full-year 2026 net sales guidance to $620 million to $635 million, up from the previous range of $600 million to $620 million.
- iDose TR, a key product, generated approximately $54 million in sales during the first quarter, demonstrating strong clinical outcomes and driving physician interest and adoption.
- The international glaucoma franchise delivered record net sales of $35.8 million, with a year-over-year growth of 23% on a reported basis.
- Epioxa, a novel advancement in corneal cross-linking, has been commercially launched, with encouraging initial feedback from surgeons and the broader ophthalmic community.
- The company anticipates new competitive product trialing headwinds in some major international markets throughout 2026.
- Currency tailwinds that benefited the international glaucoma franchise are expected to abate going forward.
- Initial patient access to Epioxa is gated by typical payer adoption headwinds and hurdles, which could slow down the adoption process.
- The transition from Photrexa to Epioxa is expected to cause volatility in the Corneal Health franchise, particularly in Q2 and Q3.
- There are ongoing challenges with reimbursement in certain regions, such as CGS and WPS, which could impact the adoption of iDose.
Welcome to Glaukos Corporation's first quarter 2026 financial results conference call. Copies of the company's press release and quarterly summary document, both issued after the market close today, are available at www.glaukos.com.
(Operator Instructions) This call is being recorded.
And an archived replay will be available online in the Investor Relations section at www.glaukos.com. I will now turn the call over to Chris Lewis, Vice President of Investor Relations and Corporate Affairs.
Thank you, and good afternoon. Joining me today are Glaukos Chairman and CEO, Tom Burns; President and COO, Joe Gilliam; and CFO, Alex Thurman.
Similar to prior quarters, the company has posted a document on its Investor Relations website under the Financials and Filings Quarterly Results section titled Quarterly summary. This
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
